|
Don’t miss our top 5 cancer-related stories this month,
including a guest commentary from an industry leader, our two-part series on
trends in cancer research and more!
Revolutionizing and
personalizing global health
By E. Kevin Hrusovsky, PerkinElmer Inc. As the complexity and volume of data continue to rise, bioinformatics is emerging as one of the cornerstones of personalized medicine, from enabling discovery and development of novel treatments and diagnostics to facilitating collection, analysis and interpretation of data that ultimately helps an individual patient. SPECIAL REPORT PART 1: ‘Good enough’ is no longer good enough By Randall Willis, ddn Features Editor Aiming beyond the standard of care in oncology SPECIAL REPORT PART 2:
An aside on side effects
By Randall Willis, ddn Features Editor Are we really making things better for cancer patients? High-profile oncology partnership By Jim Cirigliano, ddn Contributing Editor Araxes Pharma and Janssen Biotech ink oncology drug development deal Natural neighbors By Kelsey Kaustinen, ddn Features Editor OSU, Biosortia link up to identify natural products for potential cancer treatments |
GDBP gains license to monoclonal antibody for China
April 2012
SHARING OPTIONS:
GANSU, China—Privately held Apexigen and Gansu Duyiwei
Biological Pharmaceutical (GDBP) have announced a collaboration that will
provide GDBP with an exclusive license to develop and commercialize APX004 in
China. APX004 is a humanized monoclonal antibody directed against VEGFR2 for
the treatment of certain cancers and angiogenic diseases. Under the agreement,
GDBP will be solely responsible for researching, developing and commercializing
APX004 in China, while Apexigen will collaborate with GDBP to advance the
development program and will retain all rights to the compound outside of
China. Apexigen will receive an upfront payment, regulatory milestone payments
and a royalty, though no specific financial details were disclosed. Zhiping
Duan, CEO of GDBP, said the deal will become a developmental milestone for the
company. Back |
|
||
|









